Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 15 Aug 2023
Cipaglucosidase alfa and miglustat for the treatment of patients with late-onset Pompe disease
15 August 2023 - NICE has published evidence-based recommendations on the use of cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for ...
Posted by Michael Wonder on 15 Aug 2023
New treatments for people with chronic migraine and soft tissue sarcoma added to the PBS
14 August 2023 - From August 2023, Australians with chronic migraine and soft tissue sarcoma will have access to new ...
Posted by Michael Wonder on 14 Aug 2023
Insurers won’t cover new Alzheimer’s treatment for some customers
12 August 2023 - Some private insurers are balking at paying for the first drug fully approved to slow mental ...
Posted by Michael Wonder on 14 Aug 2023
How advocates pushed big pharma to cut tuberculosis drug prices
14 August 2023 - The world’s best tuberculosis drug was too expensive for sufferers—until advocates and a YouTube star changed almost ...
Posted by Michael Wonder on 14 Aug 2023
FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma
14 August 2023 - Today, the FDA granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer), a bispecific B-cell maturation antigen directed ...
Posted by Michael Wonder on 14 Aug 2023
US FDA approves first therapeutic indication for Revance’s Daxxify (daxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia
14 August 2023 - Approval expands the Daxxify label to include efficacy data over the 52 week ASPEN repeat dose clinical ...
Posted by Michael Wonder on 14 Aug 2023
In the case of a devastating disease, the FDA weighs an experimental drug’s muddled data and a desperate need
14 August 2023 - Emma Albee knows the experimental drug she takes is not a cure. It won’t allow her ...
Posted by Michael Wonder on 14 Aug 2023
What Mark Cuban gets wrong about prescription drugs
10 August 2023 - Mark Cuban, the Dallas Mavericks owner and “Shark Tank” star, has been making headlines recently with his ...
Posted by Michael Wonder on 14 Aug 2023
Valneva announces PDUFA date extension for Chikungunya virus vaccine candidate
14 August 2023 – Valneva today announced that the US FDA has revised the PDUFA action date for the biologics ...
Posted by Michael Wonder on 14 Aug 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee (August 2023)
14 August 2023 - Additional documents are now available. ...
Posted by Michael Wonder on 12 Aug 2023
Jacobio Pharma announces breakthrough therapy designation from China CDE for KRAS G12C inhibitor glecirasib for the treatment of pancreatic cancer
7 August 2023 - Jacobio Pharma today announced that Jacobio's in house KRAS G12C inhibitor glecirasib was granted breakthrough therapy designation ...
Posted by Michael Wonder on 11 Aug 2023
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA mutated metastatic castration-resistant prostate cancer
11 August 2023 - Today, the FDA approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech), ...
Posted by Michael Wonder on 11 Aug 2023
US FDA designates PYC's lead as a fast track development program
11 August 2023 - The Company is currently evaluating the safety/tolerability and efficacy of an investigational drug candidate with disease-modifying potential ...
Posted by Michael Wonder on 11 Aug 2023
PHARMAC proposes widening access to a brain cancer treatment to help reduce the impact of a discontinuation
11 August 2023 - PHARMAC is proposing to widen access to temozolomide, an oral anti-cancer treatment, for people with a type ...
Posted by Michael Wonder on 10 Aug 2023
Patient and citizen participation at the organisational level in health technology assessment: an exploratory study in five jurisdictions
8 August 2023 - While patient participation in individual health technology assessments has been frequently described in the literature, patient and ...